Anne Moscona, M.D.
Dr. Anne Moscona is Attending Pediatrician at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, Professor of Pediatrics and of Microbiology and Immunology, and Vice Chair for Research of Pediatrics at Weill Cornell Medical Center. She also serves as Director of the Division of Pediatric Infectious Diseases.
She received her undergraduate degree in Biochemistry and Molecular Biology from Harvard University in 1978, her M.D. from Columbia University College of Physicians and Surgeons in 1982 and completed her residency and fellowship training at the Mount Sinai School of Medicine, where she initiated her research program and later developed and directed the Pathogenesis and Mechanisms of Host Defense (Microbiology/Immunology) course in the Medical School.
Renowned for her research in paramyxovirus biology, Dr. Moscona is active in training faculty, fellows, medical students and graduate students in pediatric infectious diseases and in virology research. She serves on national grant review committees, including those at the National Institutes of Health. Her infectious diseases and basic virology studies bridge clinical pediatrics and basic pathogenesis research, with a focus on translating fundamental virology to future therapeutics. Her honors include election to the American Society of Clinical Investigation (ASCI) and Fellowship in the American Academy of Microbiology.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.
- AETNA [HMO]
- AETNA [PPO]
- AETNA [Medicare]
- Aetna - Weill Cornell [POS]
- Affinity Health Plan
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [EPO]
- Fidelis Care
- Health First
- Health Insurance Plan of NY (HIP)
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Plus - Amerigroup
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Freedom]
- Oxford Health Plans [Medicare Advantage]
- Rockefeller University - CoreSource
- United Empire
- United Health Care
- United Health Care [Medicare]
- United Health Care [Community Plan]
•Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. The Journal of Clinical Investigation 115: 1688-1698, 2005.
•Moscona A. Neuraminidase inhibitors for influenza. New England Journal of Medicine 353:1363-1373, 2005.
•Moscona A. Oseltamivir resistance – Disabling our influenza defenses. New England Journal of Medicine 353: 2633-2636, Dec 22, 2005.
•Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A. Inhibition of Hendra virus fusion. Journal of Virology 80 (19): 9837-9849, 2006.
•Porotto M, Fornabaio M, Kellogg GE, Moscona A. A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism. Journal of Virology 81(7): 3216-28, 2007.
•Palermo LM, Porotto M, Greengard O, and Moscona, A. Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II by pH. Journal of Virology 81 (17), 9152-9161, 2007.
•Porotto M, Orefice G, Yokoyama C, Mungall B, Realubit R, Sganga M, Aljofan M, Whitt M, Glickman F, and Moscona A. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. Journal of Virology May; 83(10):5148-55, 2009. Epub 2009 Mar 4.
•Moscona A. Global Transmission of Oseltamivir-Resistant Influenza. New England Journal of Medicine Mar 5; 360(10):953-6, 2009.
•Moscona A, Porotto M, Palmer S, Tai C, Aschenbrenner L, Triana-Baltzer G, Li H, Wurtman D, Niewiesk S, Fang F.. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. Journal of Infectious Diseases 202 (2): 234-241, 2010.
•Porotto M, Yokoyama C, Palermo LM, Mungall B, Aljofan M, Cortese R, Pessi A, and Moscona A. Viral entry inhibitors targeted to the membrane site of action. Journal of Virology 84 (13): 6760-6768, 2010.
•Porotto M, Rockx B, Yokoyama CC, Talekar A, DeVito I, Palermo LM, Cortese R, Lu M, Feldmann H, Pessi A, Moscona A. Inhibition of Nipah virus infection in vivo: Targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathogens 6 (10): e1001168. doi:10.1371/journal.ppat.1001168, 2010.
•Porotto M, Yi F, Moscona A*, LaVan DA* Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human viruses. PloS One 6(3): e16874. doi:10.1371/journal.pone.0016874. (*Co-corresponding authors), 2011
•Farzan, S, Palermo, LM., Yokoyama, CC., Orefice, G., Fornabaio, M., Sarkar, A., Kellogg, GE., Greengard, O., Porotto, M., and Moscona, A. Premature activation of the paramyxovirus fusion protein before target cell attachment: corruption of the viral fusion machinery. Journal of Biological Chemistry Nov 4;286(44):37945-54, 2011. Epub 2011 Jul 28.
•Porotto, M., DeVito, I., Palmer, S., Yee, J., Yokoyama, CC., Pessi, A., and Moscona, A. , Spring-loaded model revisited: Paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein. Journal of Virology Dec;85(24):12867-80, 2011. Epub 2011 Oct 5.
•Porotto M, Palmer S, Palermo L, and Moscona A. Mechanism of fusion triggering by paramyxoviruses: Communication between viral glycoproteins during entry. Journal of Biological Chemistry Jan 2;287(1):778-93, 2012. Epub 2011 Nov 22.
•Talekar A, Pessi A, Glickman F, Sengupta U, Briese T, Whitt MA, Mathieu C, Horvat B, Moscona A, Porotto M. Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. PLoS One ;7(3):e30538, 2012. Epub 2012 Mar 2
•Porotto M, Salah Z, Devito I, Talekar A, Palmer SG, Xu R, Wilson IA, Moscona A. The second receptor binding site of the globular head of the Newcastle disease virus (NDV) hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion. J Virol. 2012 May;86(10):5730-41. Epub 2012 Mar 21.
•Palmer, S., Porotto, M., Palermo, L.M., Cunha, L., Greengard, O., Moscona, A. Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue. mBio. 2012 Jun 5;3(3). pii: e00137-12. doi: 10.1128/mBio.00137-12. Print 2012.
•Porotto M, Salah ZW, Gui L, Devito I, Jurgens EM, Lu H, Yokoyama CC, Palermo LM, Lee K, Moscona A. Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pre-triggered state. J Virol. 2012 Dec;86(23):12838-48. doi: 10.1128/JVI.01965-12. Epub 2012 Sep 19.
Honors and Awards
Charles H. Revson Foundation Fellowship for Biomedical Research 1985-1988
NIH Physician Scientist Award (NIAID), 1987
Solomon Silver Award in Clinical Medicine, 1991
Hirschl/Monique Weill-Caulier Career Scientist Award, 1992-1997
Pediatric Infectious Disease Society Young Investigator Award, 1992
Elected to membership in The Society for Pediatric Research (SPR), 1992
Elected to the American Society of Clinical Investigation (ASCI), 2001
Chair, Paramyxovirus sessions, American Society of Virology Annual Meetings, 1999 - 2011
Hattie Alexander Lecturer, Babies Hospital Alumni Day, Columbia University College of Physicians & Surgeons, 2004
Burroughs Wellcome Fund Pathogenesis of Infectious Disease Award Advisory Committee, 2006 to present
Elected Fellow, American Society for Microbiology (2009)
- Global Health
- Travel Health
- Respiratory Infection
- Viral Infection
Contact and Practices
- M.D., Columbia University College of Physicians and Surgeons, 1982